Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.
The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.
The Companyâ€™s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
Funding Rounds (3) - $5.9MUpdate
Board Members and Advisors (2)Update
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the...
Venture Capital Firm
Desjardins Venture Capital is the venture capital fund management arm of the Mouvement des...
GeneChem fund and the changing landscape of the genomics industry, the principals set out to...
Ventures West is one of Canada's largest privately owned venture capital companies. In...
San Francisco, CA